Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.52% | 16.65% | 36.65% | 94.88% | 116.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.52% | 16.65% | 36.65% | 94.88% | 116.26% |
| Cost of Revenue | 33.20% | -36.22% | 19.24% | 107.85% | 72.38% |
| Gross Profit | 16.62% | 21.23% | 38.28% | 94.15% | 119.47% |
| SG&A Expenses | 32.48% | 31.06% | 27.27% | 25.58% | 26.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.27% | 15.46% | 15.27% | 31.88% | 27.58% |
| Operating Income | 7.00% | 18.31% | 86.59% | 522.03% | 1,218.51% |
| Income Before Tax | 5.19% | 61.13% | 191.52% | 4,577.79% | 356.13% |
| Income Tax Expenses | -108.59% | -1,312.75% | 1,669.81% | -- | 59.34% |
| Earnings from Continuing Operations | 13.02% | 192.00% | 146.23% | 3,734.01% | 423.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.02% | 192.00% | 146.23% | 3,734.01% | 423.23% |
| EBIT | 7.00% | 18.31% | 86.59% | 522.03% | 1,218.51% |
| EBITDA | 7.67% | 18.02% | 77.13% | 474.37% | 934.25% |
| EPS Basic | 11.70% | 189.61% | 143.55% | 3,669.30% | 412.51% |
| Normalized Basic EPS | 3.96% | 12.54% | 62.10% | 218.71% | 346.77% |
| EPS Diluted | 11.64% | 192.31% | 143.40% | 3,900.00% | 409.41% |
| Normalized Diluted EPS | 3.90% | 13.74% | 63.24% | 218.28% | 339.94% |
| Average Basic Shares Outstanding | 1.18% | 0.83% | 1.09% | 1.84% | 2.08% |
| Average Diluted Shares Outstanding | 1.23% | -0.23% | 0.38% | 1.98% | 3.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |